Keryx Biopharmaceuticals (KERX) Ramps 38% Upon Trade Resumption
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Keryx Biopharmaceuticals (KERX) Continues Monumental Run-Up; Analysts See Another 40% Upside
January 29, 2013 10:50 AM ESTKeryx Biopharmaceuticals, Inc. (NASDAQ: KERX) continues to surge on the back of positive Phase III trial evaluating Zerenex. After yesterday's 77% surge, shares are up another 37% early Tuesday.
A number of analysts are out positive on the stock and have new price target showing... More
Oppenheimer Lifs PT on Keryx Biopharmaceuticals (KERX) to $11
January 29, 2013 8:42 AM ESTOppenheimer boosted its price target on Outperform-rated Keryx Biopharmaceuticals (NASDAQ: KERX) from $3 to $11 following positive Phase III trial evaluating Zerenex for the treatment of hyperphosphatemia in dialysis patients.
Analyst Boris Peaker, PhD comments, "Primary and key secondary endpoints were met and the... More
Stifel Nicolaus Boosts Keryx Biopharmaceuticals (KERX) PT to $13
January 29, 2013 8:37 AM ESTStifel Nicolaus raised its price target on Buy-rated Keryx Biopharmaceuticals (NASDAQ: KERX) from $4 to $13 following positive Phase 3 results for Zerenex.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more... More
Burrill Lifts PT on Keryx Biopharmaceuticals (KERX) to $11
January 29, 2013 8:04 AM ESTBurrill raised its price target on Keryx Biopharmaceuticals (NASDAQ: KERX) from $6 to $11 following positive Phase 3 results for Zerenex. The firm maintained a Market Outperform rating.
"Based on the clinically differentiated profile demonstrated in the Phase 3 clinical study, we believe Keryx should... More
Keryx Biopharmaceuticals (KERX) Gets Another 'Going to $15' Call
January 28, 2013 12:48 PM ESTAnother analyst is on the Keryx Biopharmaceuticals (NASDAQ: KERX) 'going to $15' bandwagon following positive Phase 3 data.
In addition to Roth Capital... More
Roth Capital Doubles PT on Keryx (KERX); Sees Another 200% Upside
January 28, 2013 11:27 AM ESTRoth Capital's Joseph Pantginis boosted his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) from $7 to $15 following his morning's... More
Keryx Biopharmaceuticals (KERX) to resume trading at 7:30AM
January 28, 2013 7:24 AM ESTKeryx Biopharmaceuticals, Inc. (NASDAQ: KERX) to resume trading at 7:30AM ET following positive Phase 3 data. The long-term Phase 3 study of Zerenex met primary and secondary endpoints.... More
Keryx (KERX) Says Zerenex Phase 3 Met Primary, Secondary Endpoints
January 28, 2013 7:07 AM ESTKeryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced successful top-line results from the long-term Phase 3 study of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. In this study, Zerenex met the study's primary endpoint, described below, demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Efficacy Assessment Period of the study. In addition, Zerenex met the key secondary endpoints of increasing ferritin and transferrin saturation (TSAT) and reducing... More
